Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Beats Revenue Estimates (Revised)

This article was originally published on Nasdaq

Intercept Pharmaceuticals (ICPT) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.33 per share a year ago. These figures are adjusted for non-recurring items.

Responses